In line with our previous reports of this trial where patients were classified according to either KRAS exon 2–3/BRAF or extended RAS tissue mutational status25,29,30, adding cetuximab to chemotherapy and chemoradiotherapy did not significantly improve the outcome of wild-type tumours. This evidence concerns the gene BRAF and neoplasm.